CHF Solutions, Inc. (NASDAQ:CHFS) is expected to report third quarter earnings results, before market open, on Tuesday 10th November 2020.
Previous Quarter Performance
CHF Solutions, Inc. posted loss for the second quarter of $ 0.10 per share, from the revenue of $ 1.86 million. Street analysts expected CHF Solutions, Inc. to report loss of $ 1.26 per share on revenue of $ 1.30 million for the second quarter. The bottom line results beat street analysts by $ 1.16 or 92.06 percent, at the same time, top line results outshined analysts by $ 0.56 million or 43.08 percent.
Stock Performance
Shares of CHF Solutions, Inc. traded up $ 0.25 or 3.98 percent on Monday, reaching $ 6.53 with volume of 208.70 thousand shares. CHF Solutions, Inc. has traded high as $ 6.62 and has cracked $ 6.29 on the downward trend
According to the previous trading day, closing price of $ 6.53, representing a 2,142.86 % increase from the 52 week low of $ 0.28 and a 20.51 % decrease over the 52 week high of $ 7.90.
The company has a market capital of $ 17.87 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
CHF Solutions, Inc. will be hosting a conference call at 9:00 AM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.chf-solutions.com
CHF Solutions, Inc., a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The companys commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Its Aquadex FlexFlow system includes a console, and disposable blood set and catheter.
